Iterum Therapeutics

News

Iterum has launched Orlynvah as a treatment for uncomplicated urinary tract infections (uUTIs), the first oral option in the go-to penem class.

News

Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.